Telemetry Investments’s Esperion Therapeutics ESPR Stock Holding History

Telemetry Investments’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$442K	Buy	+71,000	New	+$508K	0.7%	35
2022 Q2	–	Sell	-17,500	Closed	-$81K	–	180
2022 Q1	$81K	Sell	17,500 -33,000	-65%	-$142K	0.13%	110
2021 Q4	$252K	Buy	+50,500	New	+$404K	0.32%	103
2019 Q2	–	Sell	-7,500	Closed	-$301K	–	94
2019 Q1	$301K	Buy	+7,500	New	+$336K	0.15%	65
2016 Q3	–	Sell	-20,500	Closed	-$203K	–	112
2016 Q2	$203K	Sell	20,500 -12,500	-38%	-$207K	0.11%	89
2016 Q1	$558K	Sell	33,000 -19,000	-37%	-$306K	0.16%	55
2015 Q4	$1.16M	Buy	+52,000	New	+$1.31M	0.39%	44

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Telemetry Investments's ESPR Position: Q4 2022 in Review

Telemetry Investments opened a new position in Esperion Therapeutics (ESPR) in Q4 2022: 71,000 shares worth $442K. The stake represents 0.7% of the portfolio and ranks #35 among its holdings. This is a return to the name: Telemetry Investments previously reported a position in ESPR as recently as Q1 2022.

Telemetry Investments first reported a position in ESPR in Q4 2015 and has held it in 7 quarters since. The position peaked at $1.16M in Q4 2015. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2022.

Telemetry Investments held 71,000 shares of Esperion Therapeutics worth $442K as of Q4 2022.
Esperion Therapeutics was a new Telemetry Investments position in Q4 2022.
Esperion Therapeutics made up 0.7% of Telemetry Investments's portfolio in Q4 2022, its #35 holding.
Telemetry Investments first reported a position in Esperion Therapeutics in Q4 2015 and has held it in 7 quarters since.
Telemetry Investments's Esperion Therapeutics position peaked at $1.16M in Q4 2015.
165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2022.

Based on Telemetry Investments's 13F filing for Q4 2022, filed 14 Feb 2023.